NextCure (NASDAQ: NXTC) — Perfil da empresa, notícias e dados financeiros
NextCure is a biotechnology firm focused on novel immunotherapies for cancer and immune-related diseases.

NextCure
NextCure (NASDAQ:NXTC) is a biotechnology company focused on discovering and developing novel immunotherapies for cancer and other immune-related diseases. By leveraging its proprietary FIND-IO™ platform, NextCure aims to identify and advance therapeutic proteins and peptides that harness the body's immune system to fight disease effectively. The company's pipeline of projects includes several promising candidates in different stages of development, aimed at addressing unmet medical needs across various oncological indications. With a commitment to innovation and patient welfare, NextCure's objective is to push the boundaries of scientific research to provide new, effective treatments that improve patient outcomes and quality of life.
Resumo
Operações
Produtos e/ou serviços de NextCure
- NC318, an immunomedicine targeting Siglec-15, aimed at enhancing immune system's ability to fight cancer.
- NC410, a novel immune modulator designed to restore immune recognition and kill cancer cells.
- NC762, a monoclonal antibody that targets B7-H4, potentially inhibiting tumor growth.
- Collaboration with Yale University to identify novel cancer targets, leveraging NextCure's FIND-IO platform.
equipe executiva do NextCure
- Michael S. RichmanCo-Founder, CEO, President & Director
- Timothy MayerChief Operating Officer
- Udayan GuhaChief Medical Officer
- Lieping ChenCo-Founder & Chairman of Scientific Advisory Board
- Steven P. CobournChief Financial Officer
- Kevin G. ShawSenior VP & General Counsel
- Sourav KunduSenior Vice President of Development & Manufacturing
- Sebastien MalovesteSenior Vice President of Business Development
Últimas notícias sobre a NextCure
Principais indicadores financeiros
Resultados divulgados pela NextCure , em USD.
- Cap. de mercado
- 26,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -8.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -57,6 mi | -55,8 mi | |
| 0 | -59,7 mi | -55,7 mi | |
| 0 | -67,6 mi | -62,7 mi | |
| 0 | -75,9 mi | -69,4 mi |